FDA Agrees Mifepristone Is Safe Enough to Dispense by Mail

The Food and Drug Administration has announced that women no longer will have to pick up the abortion pill mifepristone (Mifeprex) in person at certain certified sites and can get a prescription via an online consultation and delivery through the mail.

In April 2021, the FDA lifted the in-person dispensing requirement for mifepristone for the duration of the COVID-19 pandemic and in December the agency made that decision permanent.

As this news organization reported on April 12, 2021, acting commissioner of food and drugs, Janet Woodcock, MD, stated that the FDA would “permit the dispensing of mifepristone through the mail when done by or under the supervision of a certified prescriber; or through a mail-order pharmacy under the supervision of a certified prescriber.”

That decision came after suspension of the in-person dispensing requirement in response to COVID-19 safety concerns for patients as well as providers associated with in-person clinic visits.

Decision comes amid Supreme Court debate

The FDA decision comes as the Supreme Court nears a decision on whether to overturn its 1973 ruling on Roe v. Wade.

Additionally, the Supreme Court on returned a lawsuit over Texas’ ban on abortions after 6 weeks to a federal appeals court that has twice allowed the law to stay in effect, rather than to a district judge who wanted it blocked.

Alexis McGill Johnson, president and CEO, of the Planned Parenthood Federation of America, said in a statement, “Abortion is time sensitive, essential health care, and this decision will remove a sometimes insurmountable barrier for patients seeking an abortion. With abortion rights at risk like never before, the FDA’s decision is a long overdue step toward expanding people’s access to safe medication abortion.”

Georgeanne Usova, senior legislative counsel at the American Civil Liberties Union told CNBC News: “The FDA’s decision will come as a tremendous relief for countless abortion and miscarriage patients.”

Catherine D. Cansino, MD, MPH, associate clinical professor in the department of obstetrics and gynecology at the University of California, Davis, and member of the editorial advisory board for ObGyn News said in an interview: “I think that this change is a long time coming and speaks to the fact that science matters and medicine prevails over politics. We need to protect health rights first!”

Others expressed doubt or outrage.

Fidelma Rigby, MD, a professor in the department of obstetrics and gynecology, division of maternal fetal medicine, Virginia Commonwealth University Medical Center, Richmond, said in an interview: “My concern is that what if there is an ectopic pregnancy? I’m not as enthusiastic as some of my partners would be about this announcement.”

“The FDA’s decision today places women at risk,” said Carol Tobias, president of the National Right to Life Committee. “These changes do not make this abortion process safer for women. What these changes do is make the process easier for the abortion industry.”

The antiabortion groups Charlotte Lozier Institute and the Susan B. Anthony List were among other organizations issuing statements against Dec. 16’s FDA ruling.

The FDA stated that mifepristone prescribers will still need to earn certification and training. Additionally, the agency said dispensing pharmacies will have to be certified.

The FDA said in updated guidance on its website that after conducting a review of the Risk Evaluation and Mitigation Strategy for mifepristone, it “determined that the data support modification of the REMS to reduce burden on patient access and the health care delivery system and to ensure the benefits of the product outweigh the risks.”

The modifications include:

  • “Removing the requirement that mifepristone be dispensed only in certain health care settings, specifically clinics, medical offices, and hospitals (referred to as the ‘in-person dispensing requirement’).”

  • Adding a requirement that pharmacies must be certified to dispense the drug.

The FDA said removing the in-person dispensing rule will allow delivery of mifepristone by mail via certified prescribers or pharmacies, in addition to in-person dispensing in clinics, medical offices, and hospitals.

In 2018, an expert National Academies of Science, Engineering, and Medicine panel concluded that requiring that medication abortion be provided at only certain facilities, solely by a physician or in the physical presence of certain providers, did not improve safety or quality of care.

Mifepristone is used, together with misoprostol, to end an early pregnancy. The FDA first approved Mifeprex in 2000 for use through 10 weeks’ gestation. According to the FDA, mifepristone is approved in more than 60 other countries.

Many states bar mailing of abortion pills

However, according to the Guttmacher Institute, 19 U.S. states have laws that bar telehealth consultations or mailing of abortion pills.

Reuters reported that women in those states would not be able to make use of the rule change get the drug delivered to their home but could potentially travel to other states to obtain medication abortion.

“States such as California and New York that have sought to strengthen access to abortion may make the drug available to women from other states,” Reuters reported.

Jessica Arons, senior advocacy and policy counsel for reproductive freedom at the ACLU, told CBS News, “Medication abortion is one more lens through which we see that we are witnessing a tale of two countries. Half the states are protecting access to abortion and half are trying every single way they can to eliminate access to abortion care.”

Positive results when Canada lifted restrictions

As this news organization has reported, a study found positive results when Canada lifted restrictions on access to the abortion pills and a good safety profile for mifepristone.

A study in the New England Journal of Medicine found abortion rates remained stable and adverse events were rare after mifepristone prescribing restrictions were lifted in Canada.

Senior author Wendy V. Norman, MD, professor in the department of family practice at the University of British Columbia, Vancouver, said in a statement, “Our study is a signal to other countries that restrictions are not necessary to ensure patient safety.”

Another recent study in JAMA Network Open (2021 Aug 24. doi: 10.1001/jamanetworkopen.2021.22320) found that abortion via telehealth prescriptions may be just as safe and effective as in-person care.

The study investigators said that, “of the 110 women from whom researchers collected remote abortion outcome data, 95% had a complete abortion without additional medical interventions, such as aspiration or surgery, and none experienced adverse events. Researchers said this efficacy rate is similar to in-person visits.”

This story originally appeared on MDedge.com, part of the Medscape Professional Network.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
[Editorial] 'Purge/Politics of Fear' 10 years after Kim Jong-un took power, the government closed its eyes to North Korean human rights thumbnail

[Editorial] 'Purge/Politics of Fear' 10 years after Kim Jong-un took power, the government closed its eyes to North Korean human rights

북한 김정은 국무위원장이 집권한 지 10년이 흘렀다. 김정은은 2011년 12월 17일 심근경색으로 사망한 김정일 국방위원장의 뒤를 이어 유례없는 3대 세습 정권을 물려받았다. 북한은 김정일 사망 10주기가 되는 엊그제부터 대대적인 추모행사를 진행하면서 김정은 우상화에 여념이 없다. 당 기관지 노동신문은 어제 김정은이 국가 강대성의 상징이며 “약소민족을 자존심과 창조력이 강한 위대하고 훌륭한 인민으로 키웠다”고 했다. 이런 허황한 선전·선동이…
Read More
Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer thumbnail

Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer

In patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed on enzalutamide (Xtandi), those who continued the treatment in combination with docetaxel and prednisolone saw improved progression-free survival (PFS), the phase IIIb PRESIDE study found. Median PFS was 9.53 months with the the enzalutamide-based combination compared with 8.28 months in those treated with placebo…
Read More
Responding to patients who may mistrust you thumbnail

Responding to patients who may mistrust you

People who mistrust healthcare organizations due to discrimination and other factors are less likely to take medical advice and keep follow-up appointments. Transforming Care spoke to Laura Bogart, Ph.D., a social psychologist and senior behavioral scientist at the RAND Corporation whose research has documented the effects of medical mistrust on HIV prevention and treatment outcomes
Read More
Nam-ki Hong "Promoting the planned district for the February 4 measures in October, designating the main district within the year" thumbnail

Nam-ki Hong “Promoting the planned district for the February 4 measures in October, designating the main district within the year”

"3∼4년 걸리던 민간사업 지구 지정 절차, 1년 내 단축 기대" 홍남기 부총리 겸 기획재정부 장관은 2·4대책 예정지구 지정을 10월부터 추진하고, 본지구 지정도 연내 착수하겠다고 29일 밝혔다. 홍 부총리는 이날 정부 서울청사에서 부동산시장 점검 관계장관회의를 열고 2·4대책 관련 공공주택특별법(공주법) 개정안 등의 시행에 따라 2·4대책 도심복합사업 후보지 지구지정 절차에 본격 돌입하게 됐다며 이런 내용을 설명했다. 그는 "이미…
Read More
Index Of News
Total
0
Share